Target Name: LNCAROD
NCBI ID: G101928687
Review Report on LNCAROD Target / Biomarker Content of Review Report on LNCAROD Target / Biomarker
LNCAROD
Other Name(s): LINC01468 | lncRNA activating regulator of DKK1 | LncRNA activating regulator of DKK1, transcript variant 1 | lnc-MBL2-4 | Lnc-MBL2-4 | LNCAROD variant 1 | A-ROD

LNCAROD: A Potential Drug Target and Biomarker

LncRNA (long non-coding RNA) are a class of genetic material that have been shown to play crucial roles in various biological processes. One of the most promising features of these molecules is their potential as drug targets or biomarkers. LncRNA LNCAROD has been identified as a potential drug target and biomarker, which has been the focus of extensive research in recent years. In this article, we will explore the potential of LncRNA LNCAROD as a drug target and biomarker.

Potential Drug Target

LncRNA LNCAROD is a non-coding RNA that has been shown to play a role in various cellular processes, including cell adhesion, migration, and invasion. LncRNA LNCAROD has been shown to regulate the activity of several key signaling pathways, including the NF-kappa pathway. This pathway is involved in various cellular processes, including cell growth, differentiation, and survival.

LncRNA LNCAROD has been shown to play a negative role in the NF-kappa pathway. This is associated with the development of various diseases, including cancer. For example, studies have shown that LncRNA LNCAROD can inhibit the activity of the NF-kappa pathway, which can lead to the inhibition of cell growth and the formation of tumors.

In addition to its role in the NF-kappa pathway, LncRNA LNCAROD has also been shown to play a role in the regulation of cell adhesion. This is an important process that is involved in the formation of tissues and organs, including blood vessels and neural cells. LncRNA LNCAROD has been shown to regulate the activity of several key signaling pathways that are involved in cell adhesion, including the cadherin-based signaling pathway.

Potential Biomarker

LncRNA LNCAROD has also been shown to serve as a potential biomarker for various diseases, including cancer. This is because of its role in the regulation of cell growth and the NF-kappa pathway.Studies have shown that LncRNA LNCAROD can be expressed at higher levels in cancer cells compared to normal cells. This increased expression of LncRNA LNCAROD can be used as a biomarker for cancer, as it can be used to diagnose and monitor the progression of the disease.

In addition to its potential as a drug target, LncRNA LNCAROD has also been shown to have potential as a biomarker for various other diseases, including cardiovascular disease and neurodegenerative diseases. For example, studies have shown that LncRNA LNCAROD can be expressed at higher levels in individuals with cardiovascular disease compared to those without the disease. This increased expression of LncRNA LNCAROD can be used as a biomarker for cardiovascular disease, as it can be used to diagnose and monitor the progression of the disease.

Conclusion

In conclusion, LncRNA LNCAROD has the potential to be a drug target and biomarker. Its role in the regulation of cell adhesion and the NF-kappa pathway makes it an attractive target for drug development. Furthermore, its potential as a biomarker for various diseases makes it an important tool for diagnostic and monitoring purposes. Further research is needed to fully understand the potential of LncRNA LNCAROD as a drug target and biomarker.

Protein Name: LncRNA Activating Regulator Of DKK1

The "LNCAROD Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LNCAROD comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

LNCARSR | LNCATV | LNCNEF | LNCOC1 | LNCOG | LNCPRESS1 | LNCRI | LNCRNA-ATB | LNCRNA-IUR | LNCTAM34A | LNP1 | LNPEP | LNPK | LNX1 | LNX1-AS1 | LNX2 | LOC100127946 | LOC100127955 | LOC100128002 | LOC100128028 | LOC100128050 | LOC100128059 | LOC100128079 | LOC100128093 | LOC100128164 | LOC100128242 | LOC100128288 | LOC100128317 | LOC100128361 | LOC100128398 | LOC100128494 | LOC100128593 | LOC100128770 | LOC100128966 | LOC100128988 | LOC100129034 | LOC100129098 | LOC100129148 | LOC100129175 | LOC100129203 | LOC100129215 | LOC100129316 | LOC100129381 | LOC100129434 | LOC100129455 | LOC100129534 | LOC100129603 | LOC100129697 | LOC100130000 | LOC100130207 | LOC100130285 | LOC100130298 | LOC100130331 | LOC100130452 | LOC100130463 | LOC100130548 | LOC100130587 | LOC100130691 | LOC100130698 | LOC100130744 | LOC100130748 | LOC100130872 | LOC100130899 | LOC100130938 | LOC100130987 | LOC100130992 | LOC100131096 | LOC100131107 | LOC100131257 | LOC100131289 | LOC100131372 | LOC100131496 | LOC100131532 | LOC100131626 | LOC100131635 | LOC100131859 | LOC100131877 | LOC100131943 | LOC100132004 | LOC100132062 | LOC100132077 | LOC100132078 | LOC100132249 | LOC100132287 | LOC100132356 | LOC100132609 | LOC100132626 | LOC100132651 | LOC100132686 | LOC100132741 | LOC100132781 | LOC100132797 | LOC100133077 | LOC100133165 | LOC100133177 | LOC100133284 | LOC100133331 | LOC100133920 | LOC100134317 | LOC100134368